share_log

Regeneron Pharmaceuticals | 10-Q: Q3 2024 Earnings Report

Regeneron Pharmaceuticals | 10-Q: Q3 2024 Earnings Report

再生元製藥公司 | 10-Q：2024財年三季報
美股SEC公告 ·  2024/10/31 07:21

Moomoo AI 已提取核心訊息

Regeneron Pharmaceuticals reported robust Q3 2024 financial results, with total revenue increasing 11% to $3.72 billion and net income rising 33% to $1.34 billion compared to Q3 2023. EYLEA HD and EYLEA U.S. net product sales grew to $1.54 billion, while global Dupixent sales surged 23% to $3.82 billion. Operating expenses increased 13% to $2.54 billion, reflecting higher R&D and commercialization investments.The company continued to advance its pipeline with multiple regulatory milestones. EYLEA HD received approvals in the EU and Japan for wet AMD and DME. Dupixent was approved in the U.S. for COPD and adolescent CRSwNP. However, the FDA issued Complete Response Letters for odronextamab in lymphoma and linvoseltamab in multiple myeloma due to manufacturing facility inspection findings.Looking ahead, Regeneron maintains a strong financial position with $18.3 billion in cash and investments as of September 30, 2024. The company authorized a new $3.0 billion share repurchase program in April 2024, with $2.89 billion remaining available. Key upcoming catalysts include Phase 3 QUASAR study results for EYLEA HD in RVO and regulatory decisions for multiple product candidates.
Regeneron Pharmaceuticals reported robust Q3 2024 financial results, with total revenue increasing 11% to $3.72 billion and net income rising 33% to $1.34 billion compared to Q3 2023. EYLEA HD and EYLEA U.S. net product sales grew to $1.54 billion, while global Dupixent sales surged 23% to $3.82 billion. Operating expenses increased 13% to $2.54 billion, reflecting higher R&D and commercialization investments.The company continued to advance its pipeline with multiple regulatory milestones. EYLEA HD received approvals in the EU and Japan for wet AMD and DME. Dupixent was approved in the U.S. for COPD and adolescent CRSwNP. However, the FDA issued Complete Response Letters for odronextamab in lymphoma and linvoseltamab in multiple myeloma due to manufacturing facility inspection findings.Looking ahead, Regeneron maintains a strong financial position with $18.3 billion in cash and investments as of September 30, 2024. The company authorized a new $3.0 billion share repurchase program in April 2024, with $2.89 billion remaining available. Key upcoming catalysts include Phase 3 QUASAR study results for EYLEA HD in RVO and regulatory decisions for multiple product candidates.
再生元製藥公司發佈了2024年第三季度強勁的財務結果，總營業收入增長了11%，達到37.2億，凈利潤相比於2023年第三季度上升33%，達到13.4億。EYLEA HD和EYLEA美國的淨產品銷售額增長至15.4億，而全球Dupixent的銷售額飆升23%，達到38.2億。營業費用增長了13%，達到25.4億，反映出在研發和商業化投資方面的增加。該公司繼續推進其項目管線，取得了多個監管里程碑。EYLEA HD在歐盟和日本獲得了對溼性黃斑變性和糖尿病性水腫的批准。Dupixent在美國獲得了對慢性阻塞性肺病和青少年慢性鼻竇炎多發性息肉的批准。然而，由於製造設施檢查結果，FDA對odronexta...展開全部
再生元製藥公司發佈了2024年第三季度強勁的財務結果，總營業收入增長了11%，達到37.2億，凈利潤相比於2023年第三季度上升33%，達到13.4億。EYLEA HD和EYLEA美國的淨產品銷售額增長至15.4億，而全球Dupixent的銷售額飆升23%，達到38.2億。營業費用增長了13%，達到25.4億，反映出在研發和商業化投資方面的增加。該公司繼續推進其項目管線，取得了多個監管里程碑。EYLEA HD在歐盟和日本獲得了對溼性黃斑變性和糖尿病性水腫的批准。Dupixent在美國獲得了對慢性阻塞性肺病和青少年慢性鼻竇炎多發性息肉的批准。然而，由於製造設施檢查結果，FDA對odronextamab在淋巴瘤和linvoseltamab在多發性骨髓瘤的申請發出了完整響應函。展望未來，再生元維持強勁的財務狀況，截至2024年9月30日現金和投資總額爲183億。該公司在2024年4月授權了一項新的30億的股份回購計劃，還有28.9億可用。即將到來的關鍵催化劑包括EYLEA HD在視網膜靜脈阻塞的第三階段QUASAR研究結果以及多個產品候選人的監管決策。

該公告為獨立文件：

獨立文件1  查看翻譯

獨立文件2  查看翻譯

獨立文件3  查看翻譯

獨立文件4  查看翻譯

獨立文件5  查看翻譯

声明：本內容僅用作提供資訊及教育之目的，不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    相關股票 相關股票
    代碼 迷你走勢 最新價
    Syros Pharmaceuticals
    SYRS
    -- 0.2085
    2seventy bio
    TSVT
    -- 4.950
    Plus Therapeutics
    PSTV
    -- 1.7454
    Dogwood Therapeutics
    DWTX
    -- 11.485
    Carisma Therapeutics
    CARM
    -- 0.454
    解鎖完整榜單
    重估中國資產
    繼中國開創性的DeepSeek技術推出之後，華爾街大行重估對中國市場的投資前景。
    熱門討論
    美聯儲暫停降息，你如何調整持倉？
    美聯儲宣布基準利率維持在4.25%—4.50%不變，符合市場預期。你會如何配置資產？ 展开
    FOMC新聞發佈會，2025年1月29日